Elevance Health Inc. (ELV)
NYSE: ELV · IEX Real-Time Price · USD
535.92
+1.37 (0.26%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Elevance Health Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Elevance Health stock have an average target of 606.07, with a low estimate of 575 and a high estimate of 646. The average target predicts an increase of 13.09% from the current stock price of 535.92.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ELV stock from 16 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 6 | 6 | 6 |
| Buy | 8 | 7 | 8 | 8 | 8 | 9 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 12 | 13 | 15 | 15 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Initiates $643 | Buy | Initiates | $643 | +19.98% | Jun 24, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $600 | Buy | Reiterates | $600 | +11.96% | Jun 12, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $615 | Buy | Reiterates | $615 | +14.76% | Jun 11, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $621 → $646 | Strong Buy | Maintains | $621 → $646 | +20.54% | Jun 4, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $628 → $631 | Buy | Maintains | $628 → $631 | +17.74% | May 30, 2024 |
Financial Forecast
Revenue This Year
173.61B
from 171.34B
Increased by 1.33%
Revenue Next Year
184.75B
from 173.61B
Increased by 6.41%
EPS This Year
37.65
from 25.22
Increased by 49.28%
EPS Next Year
42.06
from 37.65
Increased by 11.71%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 182.6B | 197.1B | 209.9B | 234.7B |
| Avg | 173.6B | 184.8B | 197.1B | 225.8B |
| Low | 167.0B | 175.0B | 186.6B | 219.1B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 6.6% | 13.5% | 13.6% | 19.1% |
| Avg | 1.3% | 6.4% | 6.7% | 14.5% |
| Low | -2.5% | 0.8% | 1.0% | 11.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 39.24 | 44.42 | 49.98 | 56.63 | 60.69 |
| Avg | 37.65 | 42.06 | 47.41 | 53.77 | 58.38 |
| Low | 36.46 | 39.31 | 45.32 | 51.26 | 56.64 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 55.6% | 18.0% | 18.8% | 19.4% | 12.9% |
| Avg | 49.3% | 11.7% | 12.7% | 13.4% | 8.6% |
| Low | 44.6% | 4.4% | 7.8% | 8.1% | 5.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.